Navigation Links
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Date:12/21/2007

(including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), and anemia (29%). Twenty percent (20%) of patients experienced at least 1 episode of greater than or equal to Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus DOXIL study.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
2. Synova Healthcare to Participate in Womens Health Care in the New Millennium Conference, as Retail Distribution for the Fem-V(R) Test Kit Expands
3. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
4. 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation
5. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
6. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
7. Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
10. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
11. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Health Advocate™, Inc., the ... subsidiary of West Corporation, is introducing its newest solution ... Costs and Enhance Quality. , The webinar will be ... ET and again at 2 PM ET. For more ... http://www.HealthAdvocate.com/Analytics or call 866.799.2655. , In an ...
(Date:7/25/2014)... could be treated more quickly after Manchester research ... and blood test on arrival, is effective in ... new study shows., The findings of a research ... Journal, could potentially make a huge difference to ... the most common reason for emergency hospital admission. ...
(Date:7/25/2014)... A probiotic that prevents obesity could be on ... in the gut inhibit weight gain, insulin resistance ... in mice, Vanderbilt University investigators have discovered. , ... to human," said senior investigator Sean Davies, Ph.D., ... most of the negative consequences of obesity in ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... JDRF’s revenue and spending during fiscal year 2013 (July 1, ... National Institutes of Health (NIH), the JDRF is the largest ... It has global reach and relationships with most of ... positioned to deliver a cure for type 1 diabetes in ...
(Date:7/25/2014)... -- Dietary changes can dramatically alter the balance of ... to a new study. These fluctuations could ... ease flare-ups for people with certain chronic illnesses, such ... the researchers said. Trillions of bacteria live in ... isn,t well understood, the Massachusetts Institute of Technology (MIT) ...
Breaking Medicine News(10 mins):Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Vanderbilt study examines bacteria's ability to fight obesity 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2
... 2.1 Million Teens ... ... 2009 -- With an estimated 2,500 children ages 12 to 17 taking a prescription painkiller ... with MedSafe, the developers of a state-of-the-art medication lock-box, to curb the problem where it ...
... worker study suggests more potential hazards from the plastics ... to high levels of the controversial plastics chemical bisphenol ... including impotence and low sex drive, among Chinese factory ... researchers stressed that the workers were exposed to BPA ...
... ... is the inspiration for a new film which will find its way onto the ... ... event, the Molecular Medicine Tri-Conference (February 3-5, 2010) will feature inspirational Keynote John F. ...
... The Quigley Corporation, (Nasdaq: QGLY) , ... a conference call in which Ted Karkus, Chairman and CEO, will ... results and Q&A. , The conference call will be ... www.quigleyco.com ), at 11:00 AM (ET) on Thursday, November 12, ...
... LONDON, November 11 Extensive research conducted ... University of,Sheffield on the Simbionix PROcedure Rehearsal Studio(TM), was ... 2009 congress in Lisbon, Portugal. , ... year, is,the world,s first patient specific system to enable ...
... ... home or office using methods and products that are government-approved, but that won,t harm your ... Rhinebeck, ... The Natural Flu Protection Kit, the first product to emerge from the company’s partnership with ...
Cached Medicine News:Health News:D.A.R.E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 2Health News:D.A.R.E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 3Health News:BPA Tied to Impotence in Men 2Health News:BPA Tied to Impotence in Men 3Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 2Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 3Health News:The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 3Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 2Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 3
(Date:7/24/2014)... HILDEN , Germany , and ... , Exclusive global ... assays for SF3B1 mutations, including next-generation sequencing (NGS) gene ... gene, to be targeted by new test, indicate favorable ... myelodysplastic syndromes  QIAGEN sees potential for developing ...
(Date:7/24/2014)... , July 24, 2014 Amgen (NASDAQ: ... quarter financial results on Tuesday, July 29, 2014, after the ... followed by a conference call with the investment community at ... be Robert A. Bradway , chairman and chief executive ... Live audio of the conference call will be simultaneously ...
(Date:7/24/2014)... , July 24, 2014 Many new dentists who ... do to ensure that their practice will be a success. ... basic supplies they use the most can make all the ... dentists have recently discovered that purchasing discount dental supplies ... According to successful dentists across the ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2Dental Supplies Online is Key to Dental Success...Really! 2
... 1, 2012 The FDA and representatives from the ... on proposed recommendations for the third reauthorization of a ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The recommendations would authorize the ... five years, plus adjustments for inflation. Details of the ...
... Corporation (NYSE: BSX ) announces first ... PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent ... the new device was performed by Professor Antonio ... at Columbus Hospital and San Raffaele Hospital in ...
Cached Medicine Technology:FDA and Industry Reach Agreement in Principle on Medical Device User Fees 2FDA and Industry Reach Agreement in Principle on Medical Device User Fees 3Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 2Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 3Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: